BioSkryb Genomics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 55

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $20M

  • Investors
  • 3

BioSkryb Genomics General Information

Description

Developer of a genome amplification system designed to utilize cellular heterogeneity. The company transforming through its single-cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome and proteome within a single cell to understand the drivers, mechanisms and management of complex diseases and transform single-cell molecular discovery and analysis, enabling medical researchers and clinicians to elucidate the mechanisms of pathology in the genome.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2810 Meridian Parkway
  • Suite 110
  • Durham, NC 27713
  • United States
+1 (919)
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • 2810 Meridian Parkway
  • Suite 110
  • Durham, NC 27713
  • United States
+1 (919)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioSkryb Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-May-2025 $20M Completed Generating Revenue
1. Seed Round 17-May-2019 Completed Generating Revenue
To view BioSkryb Genomics’s complete valuation and funding history, request access »

BioSkryb Genomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 2
Seed
To view BioSkryb Genomics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BioSkryb Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a genome amplification system designed to utilize cellular heterogeneity. The company transforming through
Biotechnology
Durham, NC
55 As of 2025

Oxford, United Kingdom
 

Boulder, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioSkryb Genomics Competitors (6)

One of BioSkryb Genomics’s 6 competitors is Oxford Nanopore Technologies, a Formerly VC-backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Nanopore Technologies Formerly VC-backed Oxford, United Kingdom
Watchmaker Genomics Venture Capital-Backed Boulder, CO
New England Biolabs Corporation Ipswich, MA
Pacific BioSciences of California Formerly VC-backed Menlo Park, CA
CD Genomics Corporation Shirley, NY
To view BioSkryb Genomics’s complete competitors history, request access »

BioSkryb Genomics Patents

BioSkryb Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025085821-A1 Methods, systems, and compositions for cell storage and analysis Inactive 19-Oct-2023
EP-4784791-A1 Methods, systems, and compositions for cfdna analysis Pending 26-Sep-2023
WO-2025072326-A1 Methods, systems, and compositions for cfdna analysis Inactive 26-Sep-2023
EP-4655437-A2 Fine needle aspiration methods Pending 23-Jan-2023
US-20260218168-A1 Fine needle aspiration methods Pending 23-Jan-2023 C12N15/1096
To view BioSkryb Genomics’s complete patent history, request access »

BioSkryb Genomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioSkryb Genomics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Seed Healthcare Venture Capital Minority
Anzu Partners Venture Capital Minority
Wilson Sonsini Goodrich & Rosati VC-Backed Company Minority
To view BioSkryb Genomics’s complete investors history, request access »

BioSkryb Genomics FAQs

  • When was BioSkryb Genomics founded?

    BioSkryb Genomics was founded in 2018.

  • Where is BioSkryb Genomics headquartered?

    BioSkryb Genomics is headquartered in Durham, NC.

  • What is the size of BioSkryb Genomics?

    BioSkryb Genomics has 55 total employees.

  • What industry is BioSkryb Genomics in?

    BioSkryb Genomics’s primary industry is Biotechnology.

  • Is BioSkryb Genomics a private or public company?

    BioSkryb Genomics is a Private company.

  • What is BioSkryb Genomics’s current revenue?

    The current revenue for BioSkryb Genomics is .

  • How much funding has BioSkryb Genomics raised over time?

    BioSkryb Genomics has raised $31.5M.

  • Who are BioSkryb Genomics’s investors?

    Seed Healthcare, Anzu Partners, and Wilson Sonsini Goodrich & Rosati have invested in BioSkryb Genomics.

  • Who are BioSkryb Genomics’s competitors?

    Oxford Nanopore Technologies, Watchmaker Genomics, New England Biolabs, Pacific BioSciences of California, and CD Genomics are some of the 6 competitors of BioSkryb Genomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process